---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-057130"
form_type: "8-K"
ticker: null
cik: "0001061027"
company_name: "Viracta Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T04:44:55.638145+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Viracta Q1 net loss $9.1M; positive NAVAL-1 trial ORR 50% in EBV+ PTCL

## Summary
- Net loss $9.1M ($0.23/shr) vs $12.2M in Q1 2023; cash $39.6M sufficient into late Q1 2025.
- NAVAL-1 trial: Nana-val ORR 50%, complete response rate 20% in R/R EBV+ PTCL (n=10); median DoR maturing.
- Plan to meet FDA mid-2024 for accelerated approval; Stage 1+2 data expected Q3 2024.
- PMDA endorsed direct Japan enrollment into NAVAL-1 without prior Phase 1 safety study.
- Phase 1b/2 solid tumor study: RP2D expected H2 2024; dose-optimization cohort by year-end.

## SEC filing metadata
- accession: 0000950170-24-057130
- form_type: 8-K
- cik: 0001061027
- company_name: Viracta Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061027/000095017024057130/0000950170-24-057130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061027/000095017024057130/virx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-057130
- JSON: https://secwatch.observer/filing/0000950170-24-057130.json
- Plain text: https://secwatch.observer/filing/0000950170-24-057130.txt

## Key facts
- Earnings Releases
  Viracta Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Viracta Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024057130/0000950170-24-057130-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.